Ken Griffin’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.82M | Sell |
267,996
-469,761
| -64% | -$9.42M | ﹤0.01% | 4400 |
|
|
2025
Q4 | $17.3M | Buy |
737,757
+135,480
| +22% | +$2.94M | ﹤0.01% | 2532 |
|
|
2025
Q3 | $12M | Buy |
602,277
+59,081
| +11% | +$1.06M | ﹤0.01% | 2993 |
|
|
2025
Q2 | $7.44M | Buy |
543,196
+353,519
| +186% | +$3.39M | ﹤0.01% | 3458 |
|
|
2025
Q1 | $2.1M | Sell |
189,677
-39,108
| -17% | -$417K | ﹤0.01% | 5451 |
|
|
2024
Q4 | $2.44M | Sell |
228,785
-13,281
| -5% | -$159K | ﹤0.01% | 5223 |
|
|
2024
Q3 | $3.07M | Buy |
242,066
+167,704
| +226% | +$2.49M | ﹤0.01% | 4735 |
|
|
2024
Q2 | $1.25M | Buy |
74,362
+2,546
| +4% | +$36.2K | ﹤0.01% | 6170 |
|
|
2024
Q1 | $1.08M | Sell |
71,816
-72,063
| -50% | -$1.18M | ﹤0.01% | 6767 |
|
|
2023
Q4 | $2.16M | Buy |
143,879
+136,883
| +1,957% | +$1.78M | ﹤0.01% | 5217 |
|
|
2023
Q3 | $98K | Sell |
6,996
-40,984
| -85% | -$658K | ﹤0.01% | 10924 |
|
|
2023
Q2 | $497K | Sell |
47,980
-29,196
| -38% | -$322K | ﹤0.01% | 7958 |
|
|
2023
Q1 | $713K | Buy |
77,176
+28,239
| +58% | +$260K | ﹤0.01% | 7518 |
|
|
2022
Q4 | $434K | Buy |
48,937
+35,216
| +257% | +$334K | ﹤0.01% | 8544 |
|
|
2022
Q3 | $114K | Buy |
+13,721
| New | +$114K | ﹤0.01% | 10983 |
|
|
2021
Q4 | – | Sell |
-57,298
| Closed | -$964K | – | 14795 |
|
|
2021
Q3 | $964K | Sell |
57,298
-11,251
| -16% | -$178K | ﹤0.01% | 8253 |
|
|
2021
Q2 | $1.05M | Buy |
68,549
+30,604
| +81% | +$553K | ﹤0.01% | 8249 |
|
|
2021
Q1 | $739K | Buy |
37,945
+1,619
| +4% | +$34.4K | ﹤0.01% | 8829 |
|
|
2020
Q4 | $655K | Buy |
36,326
+11,367
| +46% | +$238K | ﹤0.01% | 7636 |
|
|
2020
Q3 | $481K | Buy |
24,959
+3,966
| +19% | +$89.8K | ﹤0.01% | 7371 |
|
|
2020
Q2 | $548K | Sell |
20,993
-47,285
| -69% | -$1.16M | ﹤0.01% | 6917 |
|
|
2020
Q1 | $1.22M | Sell |
68,278
-5,405
| -7% | -$146K | ﹤0.01% | 4974 |
|
|
2019
Q4 | $2.46M | Sell |
73,683
-21,128
| -22% | -$577K | ﹤0.01% | 4082 |
|
|
2019
Q3 | $2.26M | Sell |
94,811
-6,994
| -7% | -$229K | ﹤0.01% | 4285 |
|
|
2019
Q2 | $3.66M | Sell |
101,805
-67,844
| -40% | -$2.5M | ﹤0.01% | 3548 |
|
|
2019
Q1 | $6.27M | Sell |
169,649
-204,683
| -55% | -$8.58M | ﹤0.01% | 2673 |
|
|
2018
Q4 | $16.1M | Buy |
374,332
+98
| +0% | +$4.41K | 0.01% | 1409 |
|
|
2018
Q3 | $17.7M | Buy |
374,234
+53,200
| +17% | +$2.47M | 0.01% | 1507 |
|
|
2018
Q2 | $16M | Buy |
321,034
+239,676
| +295% | +$13.9M | 0.01% | 1506 |
|
|
2018
Q1 | $4.04M | Buy |
+81,358
| New | +$4.08M | ﹤0.01% | 2699 |
|
Other funds holding URGN
RI
KCM
JFG
PBA
ACA
Ken Griffin's URGN Position: Q1 2026 in Review
Ken Griffin reduced its UroGen Pharma (URGN) stake by 64% in Q1 2026, selling an estimated $9.42M and leaving 267,996 shares worth $4.82M. The position accounts for ﹤0.01% of the portfolio, ranked #4400.
Ken Griffin first reported a position in URGN in Q1 2018 and has held it in 30 quarters since. The position peaked at $17.7M in Q3 2018. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.
- Ken Griffin held 267,996 shares of UroGen Pharma worth $4.82M as of Q1 2026.
- Ken Griffin sold 469,761 UroGen Pharma shares in Q1 2026, an estimated $9.42M.
- UroGen Pharma made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4400 holding.
- Ken Griffin first reported a position in UroGen Pharma in Q1 2018 and has held it in 30 quarters since.
- Ken Griffin's UroGen Pharma position peaked at $17.7M in Q3 2018.
- 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.